Companies
/
Orca Bio
Healthtech
Orca Bio is a Menlo Park-based biotechnology company developing precisely engineered cell therapy products intended to make bone marrow and stem cell transplants safer and more effective for patients with blood cancers and other diseases.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Orca Bio was founded in 2016 by Ivan Dimov and Nate Fernhoff, building technology to precisely sort and purify the specific types of cells within a bone marrow or stem cell donation that are most beneficial for a successful transplant while removing or reducing cell populations associated with serious transplant complications, most notably graft-versus-host disease, a potentially severe and sometimes fatal complication in which transplanted donor immune cells attack the recipient patient's own body, a significant risk that has historically limited how safely and broadly stem cell transplants can be used to treat blood cancers and certain other diseases despite transplants' potential to be curative for patients whose disease has not responded adequately to other treatments. The company's core technology uses advanced cell sorting techniques to precisely characterize and separate different cell populations within a donor's stem cell or bone marrow donation, then formulates a more precisely engineered transplant product containing specific ratios of beneficial cell types associated with helping the transplant successfully engraft and fight any remaining cancer cells, while reducing cell populations most strongly associated with causing graft-versus-host disease and other transplant complications, an approach the company argues can improve the safety and effectiveness of stem cell transplants relative to more standard, less precisely characterized transplant preparations that have traditionally been used. Orca Bio has conducted clinical trials evaluating its engineered cell therapy products primarily for patients with blood cancers such as leukemia who are receiving a stem cell transplant, an important treatment option for many blood cancer patients but one that has historically carried significant risk given graft-versus-host disease and other transplant-related complications that Orca's technology specifically aims to reduce. The company has positioned its precisely engineered cell therapy approach as potentially expanding how safely and broadly stem cell transplantation can be used as a treatment option for eligible patients. Orca Bio has raised very substantial venture funding from investors including Altimeter Capital and Neuberger Berman, reaching a valuation exceeding $2.85 billion.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
